Read the latest news from the Division of Hematology/Oncology including awards, publications and announcements.
Director of the Maggie Daley Center Among Top 27 Breast Cancer Oncologists in the Country, Picked by Big DataWilliam Gradishar, MD, Deputy Director for the Clinical Network in the Lurie Cancer Center, is among the top 27 academic breast oncologists in the country identified in Forbes Magazine, based on "big data" analysis from Grand Rounds. This company uses a machine learning algorithm to analyze publicly available and proprietary data.Gradishar is interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professor of Breast Oncology and Director of Lurie Cancer Center’s Maggie Daley Center for Women’s Cancer Care in Prentice Women’s Hospital, where he develops and implements clinical trials of new therapeutic approaches for breast cancer.
William Gradishar, MD, on Climbing Costs of Breast Cancer Treatment Poised to Strain Medicare, NCCN“Breast cancer, particularly early-stage breast cancer, is a front-loaded illness from a resource expenditure standpoint,” said William Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Gradishar is Chair of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Breast Cancer.
- Alicia Morgans, MD, MPH receives 2017 PCF Challenge Award for her project SEARCH: Survivorship Enhancement in Men with Prostate Cancer At Risk for Poor Cognitive Health During Treatment with ADT.
An international team of scientists has pinpointed the genetic drivers of diffuse large B-cell lymphoma — the most common type of blood cancer — and determined the genes’ clinical significance. The study, published in the journal Cell, provides important insights for the development of future therapies.
Leo I. Gordon, MD, the Abby and John Friend Professor of Cancer Research, was a co-author of the study.
Suicide molecules kill any cancer cell
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules to trigger a fail-safe mechanism that may protect us from cancer.
The mechanism -- RNA suicide molecules -- can potentially be developed into a novel form of cancer therapy, the study authors said.
Cancer cells treated with the RNA molecules never become resistant to them because they simultaneously eliminate multiple genes that cancer cells need for survival.
“It’s like committing suicide by stabbing yourself, shooting yourself and jumping off a building all at the same time,” said Northwestern scientist and lead study author Marcus Peter. “You cannot survive.”
Anal Cancer More Deadly in Black Men
Al B. Benson III, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, and Chair of the NCCN Clinical Practice Guidelines in Oncology Panels for Colon, Rectal, and Anal Cancers, stated: “This report from a large cohort provides critical observations that reinforce two important concerns. First, the incidence of anal cancer is increasing secondary to rising numbers of individuals with HPV infection and the association with HIV infection. Second, healthcare disparities across diseases—including cancer—are a major problem in the United States, particularly for African American males. As tragically noted from this SEER database assessment, it is also resulting in unacceptable outcomes. The authors provide insights as to the cause of disparities and methods to address the disparities with the hope that communities across the country will intervene to assist this vulnerable population.”
Lurie Cancer Center member, Shira Dinner, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at the Feinberg School of Medicine, is one of 10 investigators nationwide to receive a 2017 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI).
A new study finds that patients with double-hit lymphoma who received autologous stem cell transplantation saw no survival benefit, compared to patients who did not undergo the procedure. Read more >>
A team of scientists has demonstrated the mechanism by which ETO2-GLIS2, a gene fusion, promotes the development of an aggressive form of pediatric leukemia. The findings, published in Cancer Cell, also reveal an opportunity for the development of therapeutics.
The study was co-authored by John Crispino, PhD, the Robert I. Lurie, MD, and Lora S. Lurie Professor of Medicine in the Division of Hematology and Oncology.